Santhera Pharmaceuticals Aktie
11,44CHF | 0,98CHF | 9,37% |
WKN DE: A3EJMQ / ISIN: CH1276028821
Aktionärsstruktur
Inhaber | in % |
---|---|
Freefloat | 76,96 |
Catalyst Pharmaceuticals, Inc. | 10,86 |
Idorsia Ltd. | 9,99 |
Santhera Pharmaceuticals Holding AG | 2,15 |
UBS (Lux) Bond Fund - Convert Europe (EUR) | 0,73 |
Swisscanto (CH) Index Fund V - Equity Fd. Switzerland To. Res. | 0,52 |
Swisscanto (CH) Index Fund V - Equity Small & Mids Caps Swit. | 0,51 |
*Die Summe der Anteile kann 100% überschreiten, da bestimmte Anteilseigner zum Freefloat dazu gerechnet wurden.
Personal
2019 | 2020 | 2021 | 2022 | 2023 | |
---|---|---|---|---|---|
Personal am Ende des Jahres | 117 | 91 | 43 | 45 | 44 |
Umsatz pro Mitarbeiter in Mio. EUR | 0,64 | 0,16 | -0,04 | 0,16 | 2,31 |
Bilanz (in Mio. CHF) - Aktiva
2019 | 2020 | 2021 | 2022 | 2023 | |
---|---|---|---|---|---|
Summe Umlaufvermögen | 49 | 18 | 25 | 3 | 35 |
Summe Anlagevermögen | 66 | 71 | 66 | 61 | 75 |
Summe Aktiva | 115 | 89 | 91 | 64 | 110 |
Bilanz (in Mio. CHF) - Passiva
2019 | 2020 | 2021 | 2022 | 2023 | |
---|---|---|---|---|---|
Summe Fremdkapital | 94 | 95 | 90 | 107 | 50 |
Summe Eigenkapital | 21 | -6 | 1 | -44 | 60 |
Summe Passiva | 115 | 89 | 91 | 64 | 110 |
Adresse
Hohenrainstrasse 24, 4133 Pratteln | |
Telefon | +41 (61) 906-89-50 |
Fax | +41 (61) 906-89-51 |
Internet | http://www.santhera.com |
Management
Ana de Vera
Deputy Chief Marketing Officer & Head-Development |
Andreas Missy
Chief of Staff |
Andrew P. Smith
Chief Financial Officer |
Bradley Carl Meyer
Director |
Dario Eklund
Chief Executive Officer |
Geert Jan van Daal
Chief Commercial Officer |
Günther Metz
Head-Business Development |
Marc Schrader
Chief Technology Officer |
Neville Kodkani
Head-Global Marketing & Partner Management |
Oliver P. Kronenberg
Secretary, Chief Legal Officer & General Counsel |
Oliver Strub
Head-Compliance |
Otto Schwarz
Director |
Philipp Gutzwiller
Independent Director |
Sabine Pilot
Head-Clinical Development Operations |
Sarah Holmes-Klotz
Global Head-People & Culture |
Shabir Hasham
Executive Director & Chief Medical Officer |
Thomas Meier
Chairman |